<DOC>
	<DOCNO>NCT00717405</DOCNO>
	<brief_summary>This single arm study ass efficacy safety preoperative treatment Avastin combine Herceptin-based chemotherapy patient primary inflammatory HER2-positive breast cancer . Patients treat total 8 cycle pre-operative chemotherapy + Avastin + Herceptin . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Plus Herceptin ( Trastuzumab ) Patients With Primary Inflammatory HER2-Positive Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>adult female , &gt; =18 year age ; inflammatory breast cancer ; HER2positive tumor ; performance status 02. metastasis ; previous treatment chemotherapy , radiation therapy hormone therapy breast tumor ; clinically significant cardiovascular disease , history thrombotic disorder .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>